Apollo Hospitals Q4FY25 Results: A Healthy Pulse & New Beds on the Way
Apollo Hospitals (APHS) wrapped up the quarter on a strong note, delivering steady revenue growth and setting ambitious targets for the future. Let’s dive into the Apollo Hospitals Q4FY25 results to see how India’s healthcare leader is performing and what it means for investors.
Solid Q4FY25 Performance
Apollo delivered consistent Q4FY25 numbers, driven by robust revenue per bed and higher occupancy in hospitals, offline pharmacies, and lifestyle clinics.
Key Financial Highlights
| Metric | Q4FY25 | YoY Growth |
|---|---|---|
Sales | ₹5,592 crore | +13% |
EBITDA | ₹770 crore | +20% |
EBITDA vs. Estimates | +2% | - |
Current Market Price (CMP) | ₹6,881 | - |
Revised Fair Value (FV) | ₹8,515 | Up from ₹8,180 |
Here’s what these numbers mean for investors:
-
Solid Financial Growth: Sales and EBITDA growth of 13% and 20%, respectively, indicate that Apollo Hospitals is consistently expanding its revenues and profitability – a positive sign for future earnings potential.
-
Beating Expectations: EBITDA outperformed internal estimates by 2%, suggesting stronger-than-expected performance and efficient cost management.
-
Positive Valuation Outlook: The revised fair value of ₹8,515 (up from ₹8,180) highlights improved long-term confidence in Apollo’s growth story, offering an upside for investors at the current market price of ₹6,881.
Apollo Hospitals Expansion Plan
| Growth Initiative | Details |
|---|---|
Bed Expansion | ~4,400 new beds in 4 years |
Existing Hospital Growth Target | Low to mid-teens growth |
Apollo plans to add approximately 4,400 new beds over the next four years. At the same time, there’s a focus on delivering low to mid-teens growth in existing hospitals—important for driving long-term success in India’s growing healthcare sector.
Key Drivers Behind Apollo’s Q4FY25 Results
| Driver | Impact |
|---|---|
ARPOB | Growing revenue per patient bed |
Occupancy Uptick | More beds filled, more patients cared for |
Robust ARPOB (Average Revenue Per Occupied Bed) and increased domestic occupancy have contributed to this steady performance. These drivers ensure each hospital is operating closer to capacity while generating higher revenue per patient.
Challenges to Keep in Mind
| Challenge | Details |
|---|---|
Bed Expansion Pace vs. Peers | Overall expansion still lower than many competitors |
Margin Drag from New Hospitals | 140 bps EBITDA margin drag expected in FY26 |
Even though 4,400 new beds is significant, competitors are expanding faster. Plus, new hospitals typically take time to turn profitable, creating temporary pressure on margins.
Future Outlook: Growth Trajectory
| Metric | Target CAGR (FY25-28E) |
|---|---|
Sales | 16% |
EBITDA | 16% |
Hospital sales and EBITDA are expected to grow at an average annual rate of 16% over the next three years, reflecting strong and consistent performance. The revised fair value target of ₹8,515—up from ₹8,180—reinforces a positive long-term Apollo Hospitals share price forecast.
Summary: Apollo Hospitals India Healthcare Story
| Strengths | Challenges |
|---|---|
Steady revenue and EBITDA growth | Bed expansion trailing competitors |
Strong occupancy and ARPOB improvements | Margin impact from new hospitals in FY26 |
4,400 new beds in 4 years | - |
Updated fair value target to ₹8,515, maintaining a positive outlook | - |
Apollo Hospitals is on a healthy growth path, with strong fundamentals and an ambitious expansion plan. While there are some challenges ahead, the consistent revenue growth and plans to add thousands of new beds position Apollo as a key player in India’s evolving healthcare landscape.
For those tracking hospital stocks in India or exploring healthcare investment opportunities, Apollo’s strong Q4FY25 results and future outlook make it a name to watch.
Investments in securities market are subject to market risks, read all the related documents carefully before investing. This information is purely backed by KSL research analyst based on research recommendation. Kotak Securities Ltd has registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. SEBI Registration No. INZ000200137 (Member of NSE, BSE, MSE, MCX & NCDEX), Member Id: NSE-08081; BSE-673; MSE-1024; MCX-56285; NCDEX-1262. Research Analyst INH000000586; BSE Enlistment No: 5035 for compliance T&C and disclaimers, Visit https://ddei5-0-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fbit.ly%2flongdisc&umid=818E14E7-34FE-7906-906B-8F0B1C42A394&auth=d2c41a7df2e2ef1fca42bbbefb1c825d24cf1548-36f3d1caa4f5ef82b030dac05eca909befcec775,
